Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for Q6DFV7

Entry ID Method Resolution Chain Position Source
AF-Q6DFV7-F1 Predicted AlphaFoldDB

60 variants for Q6DFV7

Variant ID(s) Position Change Description Diseaes Association Provenance
rs3389094431 22 K>N No EVA
rs33753991 38 S>A No EVA
rs33753989 49 N>K No EVA
rs215013648 59 N>H No EVA
rs3389086436 60 V>SDG* No EVA
rs3389104691 61 T>R No EVA
rs3389094394 69 D>H No EVA
rs3401071502 78 Q>L No EVA
rs3389094923 79 L>* No EVA
rs3389086428 100 T>S No EVA
rs3389094875 104 K>* No EVA
rs3389073632 104 K>I No EVA
rs1135251567 107 K>Q No EVA
rs253370919 109 M>V No EVA
rs1134208188 111 Q>H No EVA
rs1131780894 113 P>S No EVA
rs1135382103 115 G>S No EVA
rs3389095763 126 T>S No EVA
rs229698047 136 V>I No EVA
rs3401019210 177 P>R No EVA
rs3401020591 177 P>T No EVA
rs3389081686 197 D>N No EVA
rs3389037167 233 T>S No EVA
rs3389099488 327 K>N No EVA
rs3389103822 337 Q>K No EVA
rs33756807 348 A>V No EVA
rs33756806 352 R>G No EVA
rs242687872 359 E>K No EVA
rs33755993 360 R>H No EVA
rs257265368 366 E>Q No EVA
rs265146455 367 P>T No EVA
rs246572107 395 L>P No EVA
rs224477153 398 R>H No EVA
rs33755991 416 D>E No EVA
rs250308014 449 G>R No EVA
rs218829028 449 G>V No EVA
rs232821190 451 H>L No EVA
rs249561582 451 H>N No EVA
rs219422332 463 S>P No EVA
rs33755989 485 A>G No EVA
rs3400452123 485 A>S No EVA
rs3400452009 486 E>Q No EVA
rs33755985 497 H>Q No EVA
rs3399917909 516 D>G No EVA
rs33755103 549 I>L No EVA
rs33755101 572 D>G No EVA
rs262511183 588 P>S No EVA
rs3389099516 600 I>V No EVA
rs3389094414 724 V>SDG* No EVA
rs3389069002 727 E>G No EVA
rs3399916799 739 S>G No EVA
rs3389095756 744 K>M No EVA
rs3389095756 744 K>T No EVA
rs3389068997 762 S>C No EVA
rs216331807 779 P>T No EVA
rs3389095722 842 Q>* No EVA
rs3389086432 849 T>I No EVA
rs3389097191 852 F>S No EVA
rs3389097135 865 F>S No EVA
rs3389103795 897 G>E* No EVA

No associated diseases with Q6DFV7

2 regional properties for Q6DFV7

Type Name Position InterPro Accession
domain TLDc domain 781 - 943 IPR006571
domain LysM domain 117 - 161 IPR018392

Functions

Description
EC Number
Subcellular Localization
  • Nucleus
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

1 GO annotations of cellular component

Name Definition
nucleus A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.

2 GO annotations of molecular function

Name Definition
nuclear receptor binding Binding to a nuclear receptor protein. Nuclear receptor proteins are DNA-binding transcription factors which are regulated by binding to a ligand.
nuclear receptor coactivator activity A transcription coactivator activity that activates or increases the transcription of specific gene sets via binding to a DNA-bound nuclear receptor, either on its own or as part of a complex. Coactivators often act by altering chromatin structure and modifications. For example, one class of transcription coregulators modifies chromatin structure through covalent modification of histones. A second class remodels the conformation of chromatin in an ATP-dependent fashion. A third class modulates interactions of DNA-bound DNA-binding transcription factors with other transcription coregulators. A fourth class of coactivator activity is the bridging of a DNA-binding transcription factor to the general (basal) transcription machinery. The Mediator complex, which bridges sequence-specific DNA binding transcription factors and RNA polymerase, is also a transcription coactivator.

6 GO annotations of biological process

Name Definition
negative regulation of cellular response to oxidative stress Any process that stops, prevents or reduces the frequency, rate or extent of cellular response to oxidative stress.
negative regulation of oxidative stress-induced neuron death Any process that stops, prevents or reduces the frequency, rate or extent of oxidative stress-induced neuron death.
negative regulation of peptidyl-cysteine S-nitrosylation Any process that stops, prevents or reduces the frequency, rate or extent of peptidyl-cysteine S-nitrosylation.
positive regulation of transcription by RNA polymerase II Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter.
regulation of transcription by RNA polymerase II Any process that modulates the frequency, rate or extent of transcription mediated by RNA polymerase II.
response to oxidative stress Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of oxidative stress, a state often resulting from exposure to high levels of reactive oxygen species, e.g. superoxide anions, hydrogen peroxide (H2O2), and hydroxyl radicals.

2 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
Q8NI08 NCOA7 Nuclear receptor coactivator 7 Homo sapiens (Human) PR
Q4V8B0 Oxr1 Oxidation resistance protein 1 Rattus norvegicus (Rat) PR
10 20 30 40 50 60
MDTKEEKKEQ KERKQSYFAR LKKKKQAKQN AEIVSAASSK SRSGKDDANS DILEQDKFNV
70 80 90 100 110 120
TAEGDHSTDD KKKRKSNQLK EIRRTELKRY YSVDDNQNKT HDKKEKKMMV QKPQGTMEYT
130 140 150 160 170 180
AGSQDTLNSV ALKFNVTPNK LVELNKLFTH TIVPGQVLFV PDANISSSTI QLSSSTPGAT
190 200 210 220 230 240
VSPSSSDAEY DKLPDADLAR KALKPIERVL SSTSEEDEPG VVKFLKMNCR YFTDGKGVVG
250 260 270 280 290 300
GVMIVTPNNI MFDPHKSDPL VIENGCEEYG LICPMEEVVS IALYSDISHM KIKDALPSDL
310 320 330 340 350 360
PRDLCPLYRP GEWEDLASEK DINPFSKFKS INKEKRQQNG ERTLALDAKS VRSPEESTER
370 380 390 400 410 420
TCTRIEPPDN SELWKLKNLQ SSRGTTSESP SVTQLSMRAA LEPTAKENCL LKGDEDFVDL
430 440 450 460 470 480
EELSSQPESG INKGDATKEC LSYDQKKDGP HTVMSAKKGH VQSAQEVMGP ESDTELKGAL
490 500 510 520 530 540
DLETAEKQDE APEVDKHSGS PENLGESTLN IHEDLDKIKL IEFYLNKNKE GSQLLENVQK
550 560 570 580 590 600
SELSDRKSIE PGGIDITLSS SLPQAGDSPP EDNKEPGTLW VKGGETLPLK LDPSAEETVI
610 620 630 640 650 660
NNKEVLDSLG SSLDKMCHSA QMDNKSEIQL WLLKRIQVPI EDILPSKEEK SKTPPMFLCI
670 680 690 700 710 720
KVGKPMRKSF ASHTATMVQQ YSKRRKQPEY WFAVPRERVD HLYTFFVQWS PDVYGKDAKE
730 740 750 760 770 780
QGFVVVEKEE LNMIDNFFSE PTTKSWEIIT VEEAKRRKST CSYYEEEEEE EEGLPILQPH
790 800 810 820 830 840
SALLENMHIE QLARRLPARV QGYPWRLAYS TLEHGTSLKT LYRKSASLDS PVLLVIKDMD
850 860 870 880 890 900
NQIFGAYATH PFKFSDHYYG TGETFLYTFS PNFKVFKWSG ENSYFINGDI SSLELGGGGG
910 920 930 940
RFGLWLDADL YHGRSNSCST FNNDILSKKE DFIVQDLEVW TFE